HC Wainwright & Co. Reiterates Buy on Syros Pharmaceuticals, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on Syros Pharmaceuticals (NASDAQ:SYRS) and maintained a $15 price target.
April 01, 2024 | 11:17 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Andrew Fein reiterated a Buy rating on Syros Pharmaceuticals with a $15 price target.
The reiteration of a Buy rating and maintenance of a $15 price target by a reputable analyst could positively influence investor sentiment towards SYRS, potentially driving its stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100